Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
Rhea-AI Summary
Maze Therapeutics (Nasdaq: MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, cardiovascular and metabolic diseases, has announced the pricing of its upsized initial public offering. The company is offering 8,750,000 shares of common stock at $16.00 per share, expecting to raise gross proceeds of $140.0 million.
The shares will begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol 'MAZE'. The company has granted underwriters a 30-day option to purchase up to an additional 1,312,500 shares. The offering is expected to close on February 3, 2025. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the IPO.
AI-generated analysis. Not financial advice.
Positive
- Successful pricing of upsized IPO raising $140.0 million in gross proceeds
- Strong underwriting support from major investment banks
- Potential for additional capital through 1,312,500 share overallotment option
Negative
- Dilution of existing shareholders through new share issuance
Insights
The successful pricing of Maze Therapeutics' upsized IPO at
The high-caliber underwriting syndicate, led by J.P. Morgan and including TD Cowen, Leerink Partners and Guggenheim Securities, adds substantial credibility to the offering. These banks typically select deals with robust science and clear development pathways, indicating confidence in Maze's genetic-driven drug discovery platform and pipeline potential.
The company's focus on genetic insights for developing precision medicines in renal, cardiovascular and metabolic diseases addresses substantial market opportunities with significant unmet needs. The size of the raise should provide meaningful runway for advancing their clinical programs, particularly important given the current market emphasis on capital efficiency and clear value-creating milestones.
The inclusion of a 30-day option for underwriters to purchase up to 1,312,500 additional shares (
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as the joint bookrunning managers for the offering. The offering is being made only by means of a prospectus.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-(800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with common diseases, with a focus on renal, cardiovascular and related metabolic, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease.
For further information, please contact:
Investors:
Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
(650) 850-5080
Media:
Dan Budwick, 1AB
dan@1abmedia.com
